Inogen announces management transitions, expanded board of directors
Mr. Wilkinson will also join the Board of Directors on January 1, 2017. Mr. Wilkinson currently oversees Inogen’s global commercial, manufacturing, service, research and development, technical and support operations.
Previously, Mr. Wilkinson held various leadership roles within Inogen encompassing sales, marketing, customer service, rental revenue management, technical and repair services, and clinical services.
From 2000 to 2005, Mr. Wilkinson worked for Invacare Corporation, a designer and manufacturer of oxygen products, as a Group Product Manager and helped launch oxygen product line segment.
From 1999 to 2000, he served as a Product Line Director with Johnson & Johnson, a healthcare company.
From 1988 to 1999, he worked as a Research Scientist, Product Manager, and Project Leader at Kimberly Clark, a consumer products company.
Mr. Wilkinson received a Bachelor’s degree in Chemical Engineering from the University of Akron and an MBA from University of Wisconsin, Oshkosh.
He will succeed Raymond Huggenberger, who is retiring as Chief Executive Officer, effective March 1, 2017.
Mr. Huggenberger will continue to serve on Inogen’s Board of Directors following his retirement as Chief Executive Officer.
Inogen also announced that Scott Beardsley, Sr. Partner, Novo Ventures (US) Inc., has been appointed to Inogen’s Board of Directors, effective January 1, 2017.
Mr. Beardsley will also join the Compensation, Nominating, and Governance Committee, effective January 1, 2017.
Mr. Beardsley is employed as a Senior Partner at Novo Ventures (US), Inc., which provides certain financial investment consultancy services to Novo A/S, a Danish limited liability company that manages investments and financial assets.
Mr. Beardsley has worked within Novo A/S and its investment activities since 2009 in several roles: since January 2016, Mr. Beardsley has been employed by Novo Ventures (US) Inc. as a Senior Partner; from December 2012 through 2015, he was employed as a Partner by Novo Ventures (US) Inc.; and from 2009 through 2012, he was employed as a Senior Partner by Novo A/S.
Prior to joining Novo A/S, he was a Managing Director in the Health Care Group at J.P. Morgan, a banking and financial services company, from 2006 through 2008, and a Managing Director in the Health Care Group of US Bancorp Piper Jaffray, an investment bank, from 2001 to 2006.
Previously, Mr. Beardsley was an investment banker at US Bancorp Piper Jaffray, Montgomery Securities, an investment bank, and Kidder, Peabody & Co. Incorporated, an investment bank.
From October 2010 through May 2014, he served as a member of the board of directors of Aerocrine AB, a publicly-traded medical technology company.
Mr. Beardsley received his Masters of Business Administration from the Anderson Graduate School of Management at UCLA and his Bachelors of Science in Business Administration from Colorado State University.
Additionally, Inogen announced that Byron Myers, Founder and VP, Marketing will be promoted to EVP, Sales & Marketing, effective January 1, 2017.
Mr. Myers currently leads Inogen’s global marketing and product management operations.
Prior to serving in this position, he held various roles with Inogen in direct-to-consumer sales, marketing and product management.
Mr. Myers received a Bachelor’s degree in Economics/Mathematics from the University of California, Santa Barbara and an MBA from the Rady School of Management at the University of California, San Diego. ■
LATEST MOVES FROM California
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
More inside POST